0000000000660444

AUTHOR

Eric Francois

showing 4 related works from this author

OC-0284: First results of the French cohort ANABASE : treatment and outcome in non-metastatic anal cancer

2018

IF 4.942 (2017); International audience

Oncologymedicine.medical_specialtybusiness.industry[SDV.CAN]Life Sciences [q-bio]/Cancer02 engineering and technologyHematology021001 nanoscience & nanotechnologymedicine.diseaseOutcome (game theory)3. Good health[SDV.CAN] Life Sciences [q-bio]/CancerOncology[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieInternal medicineCohort0202 electrical engineering electronic engineering information engineeringmedicineNon metastaticAnal cancer020201 artificial intelligence & image processingRadiology Nuclear Medicine and imaging[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie0210 nano-technologybusiness
researchProduct

What is the optimal treatment for T1N0 anal squamous cell carcinoma? Analysis of current practices in the prospective French FFCD ANABASE cohort

2021

International audience; Introduction: for localized T1N0 squamous cell carcinoma of the anus (SCCA) standard radiotherapy (RT) may result in overtreatment and alternative strategies are debated. Methods: T1N0M0 SCCA treated between 2015 and 2020 by local excision (LE) or RT were analyzed from the French prospective FFCD ANABASE cohort. Treatment strategies, recurrence-free and colostomy-free survivals (RFS, CFS) and prognostic factors were reported. Results: among 1135 SCCA patients, 99 T1N0M0 were treated by LE(n = 17,17.2%), or RT ( n = 82,82.8%) including RT alone ( n = 65,79.2%) or chemo-RT ( n = 17, 20.7%). Median follow-up was 27.2 months [0.03 and ndash;54.44]. Median tumor size were…

Malemedicine.medical_specialtyLocal excisionLocal excisionmedicine.medical_treatmentAnal Canal[SDV.CAN]Life Sciences [q-bio]/CancerGastroenterologyDisease-Free Survival03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumans030212 general & internal medicineAgedRetrospective StudiesAged 80 and overUnivariate analysisHepatologyRadiotherapybusiness.industryOptimal treatmentGastroenterologyAnal Squamous Cell CarcinomaChemoradiotherapyMiddle AgedAnusAnus Neoplasms3. Good healthRadiation therapymedicine.anatomical_structureAnal canal carcinoma030220 oncology & carcinogenesisCohortCarcinoma Squamous CellFemaleFrancebusinessChemoradiotherapy
researchProduct

Treatment guidelines of metastatic colorectal cancer in older patients from the French Society of Geriatric Oncology (SoFOG)

2020

International audience; Background: Several guidelines dedicated to metastatic colorectal cancer (mCRC) are available. Since 2013 no recent guidelines are specifically dedicated to older patients and based on a systematic review. Materials and methods: A multidisciplinary Task Force with digestive oncologists, geriatricians and methodologists from the SoFOG was formed in 2016 to update recommendations on medical treatment of mCRC based on a systematic review of publications from 2000 to 2018. Search strategy has followed a standardized protocol from the formulation of clinical questions and definition of a search algorithm to the selection of complete articles for recommendations. Results: …

medicine.medical_specialtyBevacizumabColorectal cancermedicine.medical_treatment[SDV]Life Sciences [q-bio]Context (language use)Targeted therapyMetastasisMetastasisTargeted therapy03 medical and health scienceschemistry.chemical_compoundOlder patient0302 clinical medicineRegorafenibMedicineHumansChemotherapyNeoplasm MetastasisIntensive care medicineSocieties MedicalAgedNeoplasm StagingHepatologyPerformance statusbusiness.industryGastroenterologymedicine.diseaseCombined Modality TherapyColorectal cancer3. Good healthGeriatric oncologychemistry030220 oncology & carcinogenesisQuality of Life030211 gastroenterology & hepatologyFrancebusinessColorectal Neoplasmsmedicine.drug
researchProduct

Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Tr…

2021

PURPOSE Metastatic pancreatic cancer (mPC) still harbors a dismal prognosis. Our previous trial (PRODIGE 4—ACCORD 11) demonstrated the superiority of 6-month chemotherapy with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) over gemcitabine for overall survival. The high limiting oxaliplatin-related neurotoxicity supports the evaluation of an oxaliplatin stop-and-go strategy and a sequential strategy in mPC. METHODS In this phase II study, patients were randomly assigned to receive either 6 months of FOLFIRINOX (arm A), 4 months of FOLFIRINOX followed by leucovorin plus fluorouracil maintenance treatment for controlled patients (arm B), or a sequential treatment alternati…

AdultOncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentFirst lineLeucovorinIrinotecan03 medical and health sciences0302 clinical medicineInternal medicinePancreatic cancerAntineoplastic Combined Chemotherapy ProtocolsMetastatic pancreatic cancermedicineHumansNeoplasm MetastasisAgedChemotherapybusiness.industryMiddle Agedmedicine.diseaseOxaliplatinPancreatic NeoplasmsOncologyFluorouracil030220 oncology & carcinogenesisQuality of Life030211 gastroenterology & hepatologyFluorouracilbusinessmedicine.drugJournal of Clinical Oncology
researchProduct